Profile

Kerr Matthews
Title: Dr
First Name: Kerr
Surname: Matthews
Position: Lecturer
Telephone: +44 (0) 1224 262525
Email:
ORCID: ORCID Icon http://orcid.org/0000-0002-8503-7157

Connect via ResearchGate

Roles and responsibilities

  • Lecturer in Pharmaceutics, School of Pharmacy and Life Sciences.


Key research interests

Dr. Matthews’ key research interests are in the area of drug delivery and formulation science, in particular, the research and development of solid and liquid drug delivery systems. One area of specialist interest concerns the topical delivery of antimicrobial compounds to chronic wounds but more generally, the application of natural, synthetic and semi-synthetic polymers for the retention and delivery of therapeutic agents, are of historical and current interest.

Current research

Dr Matthews has supervised and co-supervised a number of funded projects at Masters and PhD level. Recent projects include:

  • Antimicrobial wafers as a novel technology for infection control in chronic wounds.
  • Development and evaluation of oral solid dosage forms for colonic delivery of drugs.
  • Investigation of the antimicrobial activity of cationic antibacterials.
  • Molecular mechanisms of diabetes mediated impaired wound healing and the development of therapeutic strategies.
  • Formulation studies on cysteamine for the treatment of nephropathic cystinosis.
  • Development of formulations for the delivery of drugs to wounds.
  • In vitro test model designed to simulate the mechanical forces exerted on a dosage form during gastric residence and emptying.

Funding

  • The development of an eye gel for the treatment of the ophthalmic complications in cystinotic patients. Co-applicant with G. Kay, D. Cairns and R. Knott, SPARKS Children’s Medical Research Charity, £101,554.
  • Development of a topical formulation base. Principal Investigator: K. Matthews, Scottish Funding Council, £4,980.
  • Formulation and evaluation of novel dosage forms of cysteamine and cysteamine prodrugs for the potential treatment of cystinosis. Co-applicant with G. Kay and D. Cairns, The Cystinosis Foundation UK, £26,355.
  • A novel topical delivery system for improved antimicrobial treatment of wound infections. Principal Investigator: K. Matthews, Tenovus Scotland, £7,333.
  • A novel topical delivery system for improved antimicrobial treatment of wound infections. Principal Investigator: K. Matthews, RGU, £48,000.
  • Formulation of a novel antioxidant as an intravenous delivery system for the treatment of stroke. Principal Investigators: K. Matthews and W.P. Chen, Rowett Institute, £7,000.
  • Development of an artificial pylorus and an investigation of dose-dumping from certain HPMC matrix tablet formulations. Principal Investigator: K. Matthews, Pfizer, £20,000.

Teaching

As a Lecturer in Pharmaceutics, Dr. Matthews teaches on a variety of MPharm modules that include, Foundations in Pharmacy Practice, Physicochemical Principles of Pharmacy, Medicine Design and Manufacture, Therapeutic Delivery, Project Introduction and Research Project.  He was also involved in the Overseas Pharmacists Assessment Programme (OSPAP).  

Background

  • BSc(Hons) in Chemistry (University of Strathclyde, 1985).
  • PhD in Chemistry (University of Strathclyde, 1989).

Professional Affiliations:

  • Member of the Royal Society of Chemistry, Chartered Chemist, CChem MRSC, 1993.
  • Member of the Academy of Pharmaceutical Sciences, MAPS, 2002.

Publications

  1. Gadad, P.C., Matthews, K.H., Knott, R.M. 2013. Silymarin released from sterile wafers restores glucose impaired endothelial cell migration. Int.J.Pharm. (accepted 04.09.13) doi:10.1016/j.ijpharm.2013.09.006
  2. O’Driscoll, N.H., Labovitiadi, O., Cushnie, T., Matthews, K.H., Lamb, A.J. 2013. Potassium loss from chlorhexidine-treated bacterial pathogens is time- and concentration-dependent and variable between species. Current Microbiology (published online 12.08.13) doi:10.1007/s00284-013-0433-3
  3. Labovitiadi, O., O’Driscoll, N.H., Lamb, A.J., Matthews*, K.H. 2013. Rheological properties of gamma-irradiated antimicrobial wafers and in vitro efficacy against Pseudomonas aeruginosa, Int.J.Pharm., 453, 462-472.
  4. Gadad, P.C., Matthews, K.H., Knott, R.M. 2013. Role of HIF1α and PKCβ in mediating the effect of oxygen and glucose in a novel wound assay. Microvascular Research., 88, 61-69.
  5. O’Driscoll, N., Labovitiadi, O., Cushnie, P.T.T., Matthews, K.H., Mercer, D.K., Lamb, A.J. 2013. Production and evaluation of an antimicrobial peptide-containing wafer formulation for topical application, Current Microbiology, 66(3), 271-278.
  6. Labovitiadi, O., Lamb, A.J., Matthews*, K.H. 2012. Lyophilised wafers as vehicles for the topical release of chlorhexidine digluconate – release kinetics and efficacy against Pseudomonas aeruginosa. Int.J.Pharm., 439(1-2), 157-164.
  7. Buchan, B., Kay, G., Matthews, K.H., Cairns, D. 2012. Suppository formulations as a potential treatment for nephropathic cystinosis. J.Pharm.Sci., 101(10), 3729-3738.
  8. Labovitiadi, O., Lamb, A.J., Matthews*, K.H. 2012.  In vitro efficacy of antimicrobial wafers against methicillin-resistant Staphylococcus aureus. Therapeutic Delivery., 3(4), 343-355.
  9. Boateng, J.S., Matthews, K.H., Auffret, A.D., Humphrey, M.J., Eccleston, G.M., Stevens, H.N.E. 2012. Comparison of the in vitro release characteristics of mucosal freeze-dried wafers and solvent-cast films containing an insoluble drug. Drug.Dev.Ind.Pharm., 38(1), 47-54.  
  10. Buchan, B., Kay, G., Heneghan, A., Matthews, K.H., Cairns, D. 2010.The preparation and evaluation of gel formulations for treatment of the ophthalmic complications in cystinosis.  Int.J.Pharm. 392(1-2), 192-197.
  11. Boateng, J.S., Matthews, K.H., Auffret, A.D., Stevens, H.N.E., Eccleston, G.M., 2010.Characterisation of freeze-dried wafers and solvent evaporated films as potential drug delivery systems to mucosal surfaces. Int.J.Pharm. 389(1-2), 24-31.
  12. Boateng, J.S., Matthews, K.H., Auffret, A.D., Stevens, H.N.E., Eccleston, G.M., 2009. In vitro drug release studies of polymeric freeze-dried wafers and solvent-cast films using paracetamol as a model soluble drug. Int.J.Pharm., 378(1-2), 66-72.
  13. Boateng, J.S., Matthews, K.H., Stevens, H.N.E., Eccleston, G.M., 2009.  Development and mechanical characterisation of solvent-cast polymeric films as potential drug delivery systems to mucosal surfaces. Drug.Dev.Ind.Pharm., 35(8), 986-996.
  14. Matthews*, K.H., 2008.  Freeze-drying of shaped pharmaceutical dosage forms.  Ind.Pharm., Issue 20, 9-11.
  15. Boateng, J.S., Matthews, K.H., Stevens, H.N.E., Eccleston, G.M., 2008.  Wound healing dressings and drug delivery systems - a review.  J.Pharm.Sci., 97(8), 2892-2923.
  16. Matthews*, K.H., Stevens, H.N.E., Auffret, A.D., Humphrey, M.J., Eccleston, G.M., 2008.  Formulation, stability and thermal analysis of lyophilised wound healing wafers containing an insoluble MMP-3 inhibitor and a non-ionic surfactant.  Int.J.Pharm., 356(1-2), 110-120.
  17. Matthews*, K.H., 2008.  A basic guide: freeze-drying of shaped pharmaceutical dosage forms.  UKICRS Newsletter., 13, 7-9.
  18. Matthews*, K.H., Stevens, H.N.E., Auffret, A.D., Humphrey, M.J., Eccleston, G.M., 2006.Gamma-irradiation of lyophilised wound healing wafers. Int.J.Pharm., 313(1-2), 78-86.
  19. Matthews*, K.H., Stevens, H.N.E., Auffret, A.D., Humphrey, M.J., Eccleston, G.M., 2005. Lyophilised wafers for wound healing containing methylcellulose as a viscosity modifier. Int.J.Pharm., 289(1-2), 51-62.
  20. Li, Y.J. Yokawa, T., Matthews, K.H., Chen, T.M., Wang, Y.F., Kodama, M., Nakaya, T., 1996. Synthesis and blood compatibility evaluation of segmented polyurethanes based on cholesterol and phosphatidylcholine analogous moieties.  Biomaterials., 17(22), 2179-2189.
  21. Li,Y.J., Matthews,K.H., Wang,Y.F., Chen, T.M., Kodama, M., Nakaya, T., 1996.  Synthesis and properties of phospholipid polyurethanes with polyisoprene soft segment.  J.Appl.Pol.Sci. 62(4), 687-694.
  22. Li,Y.J., Matthews,K.H., Chen,T.M., Wang,Y.F., Kodama, M., Nakaya, T., 1996.  Novel blood-compatible polyurethanes containing poly(butadiene) soft segments and phosphatidylcholine analogues for biomedical applications.  Chem.Mater., 8(7), 1441-1450.
  23. Li,Y.J., Matthews, K.H., Kodama, M., Nakaya, T., 1995. Novel blood-compatible polyurethanes containing long-chain alkyl groups and phosphatidylcholine analogues.  Macromol.Chem.Physic., 196(10), 3143-3153.
  24. Matthews*, K.H. and Kodama, M., 1994.  The effect of microphase separated structures on the blood contacting properties of a series of linear, segmented poly(ether urethane urea) elastomers.  Mat.Sci.Eng.C-Biomim., 2(1), 51-59.
  25. Voice, AM., Southall, JP., Rogers, V., Matthews, KH., Davies, GR., McIntyre, JE. and Ward, I.M., 1994.  Thermoreversible polymer gel electrolytes.  Polymer., 35(16), 3363-3372.
  26. Matthews*, K.H. and Kodama, M., 1993.  Measurement of the hard segment composition of segmented poly(ether urethane urea) elastomers by high-field NMR.   Polymer.Preprints.Japan., 42(8), 3322-3324.
  27. Matthews*, K.H., 1993.  Evidence for the formation of ether linkages during the synthesis of poly(ethylene phthalate).  Eur.Polym.J., 29(11), 1505-1512.
  28. Matthews*, K.H. and Pethrick, R.A. 1991.  Model studies on the cure of a polyurethane elastomer – kinetics and physical properties.  Eur.Polym.J., 27(9), 867-873.
  29. Matthews, K.H., McLennaghan, A. and Pethrick, R.A. 1987.  1H and 13C NMR model compound studies on a linear, segmented polyurethane elastomer.  Brit.Polym.J., 19(2), 165-179.